What is it about?
This review paper, therefore, attempts to summarize published literature related to “novel” enzymes that have been studied as potential biomarkers through clinical trials and randomized controlled trials in the past 12 years.
Featured Image
Why is it important?
This review examines the trends, methodologies, gaps, and updates related to these enzymes, as well as the progress of their application in clinical settings. Preferably, selecting only studies that used biological fluids as specimens, and analytical methods that are routinely done in clinical chemistry laboratories.
Perspectives
Numerous directions and opportunities within clinical enzymology exist, especially on how “novel” enzymes can serve as potential biomarkers for diagnosis, prognosis, and therapy monitoring of various diseases. As the recent advances in biochemistry and the continuing collaboration among researchers, clinicians, and industry stakeholders continue to unveil the complicated roles of enzymes in various diseases, the integration and recalibration of this “novel” enzymes into routine clinical practice holds promise for more accurate, timely, and personalized treatment strategies.
Mr. Aaron Jan Sumalde Palmares
Far Eastern University
Read the Original
This page is a summary of: Exploring the untapped potential: a systematic review of novel enzymes as biomarkers over the past 12 years, Journal of Laboratory and Precision Medicine, July 2024, AME Publishing Company,
DOI: 10.21037/jlpm-24-2.
You can read the full text:
Contributors
The following have contributed to this page
